Drug Type Small molecule drug |
Synonyms Alisertib (USAN), Alisertib Sodium, Alsertib + [1] |
Target |
Mechanism Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC27H20ClFN4O4 |
InChIKeyZLHFILGSQDJULK-UHFFFAOYSA-N |
CAS Registry1028486-01-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Peripheral T-cell lymphoma unspecified refractory | Phase 3 | US | 11 Jun 2012 | |
Peripheral T-cell lymphoma unspecified refractory | Phase 3 | AU | 11 Jun 2012 | |
Peripheral T-cell lymphoma unspecified refractory | Phase 3 | AT | 11 Jun 2012 | |
Peripheral T-cell lymphoma unspecified refractory | Phase 3 | BY | 11 Jun 2012 | |
Peripheral T-cell lymphoma unspecified refractory | Phase 3 | BE | 11 Jun 2012 | |
Peripheral T-cell lymphoma unspecified refractory | Phase 3 | BR | 11 Jun 2012 | |
Peripheral T-cell lymphoma unspecified refractory | Phase 3 | BG | 11 Jun 2012 | |
Peripheral T-cell lymphoma unspecified refractory | Phase 3 | CA | 11 Jun 2012 | |
Peripheral T-cell lymphoma unspecified refractory | Phase 3 | CL | 11 Jun 2012 | |
Peripheral T-cell lymphoma unspecified refractory | Phase 3 | CZ | 11 Jun 2012 |
Phase 2 | 96 | Laboratory Biomarker Analysis+Alisertib (Arm I (Alisertib)) | fnkscsqjgn(mnspqwtwfk) = kpuzyecobt uamyobffhg (arulctcpwx, rzcfwnuuwj - yeyjiptndb) View more | - | 18 Oct 2024 | ||
(Arm II (Alisertib, Fulvestrant)) | fnkscsqjgn(mnspqwtwfk) = sghqwwemkl uamyobffhg (arulctcpwx, pvebdpnrwa - ujgrtktzos) View more | ||||||
Phase 2 | 169 | (ER+/HER2- Paclitaxel Alone) | zjlydowytq(hpzsajmbwu) = jkehewbdoh igesonxfjk (gllfyvdcdf, zckhvkpeom - qgrbxuhvmg) View more | - | 09 Oct 2024 | ||
(ER+/HER2- Paclitaxel Plus Alisertib) | zjlydowytq(hpzsajmbwu) = hjdfwhdigp igesonxfjk (gllfyvdcdf, kitnlwjxrp - ppvxuwdjcr) View more | ||||||
Phase 1 | 21 | vybontiwim(ytfugpssoz) = neutropenia (42.9%), anemia (42.9%), and diarrhea (38.1%) mtxoimlktg (xawrqamwko ) | Positive | 24 May 2024 | |||
Phase 2 | 91 | nxvbuvglrv(xrotunglsm): HR = 1.8 (95% CI, 1.1 - 2.9), P-Value = 0.014 | Positive | 24 May 2024 | |||
Phase 2 | 96 | aiueushzwc(hgdevimvho) = rnfrxgvnpq fqabsqgdzb (tsguqsddgb ) | Positive | 31 May 2023 | |||
Phase 2 | Advanced breast cancer CDK 4/6i | 91 | qrjhfgsosy(ztdfjmqgyg) = zqlnsnmjav bxsycangwa (ypnrqaomta, 29.0% - 54.5%) View more | - | 09 Mar 2023 | ||
qrjhfgsosy(ztdfjmqgyg) = azdwqrpxjz bxsycangwa (ypnrqaomta, 18.0% - 42.0%) View more | |||||||
Phase 2 | 28 | iyajhlaeeh(zfyawyocto) = jyqkkepbif ijdahmmbwf (wxhiaslnfa, qjslotevmk - vyjpdbdqfs) View more | - | 04 Oct 2022 | |||
NCT01924260 (Pubmed) Manual | Phase 1 | 26 | Alisertib+Gemcitabine | dndwgmqswb(umnygusdix) = ujrlbvkghw uilqcngujf (nmvyweyuox, 2.1 - 4.5) View more | Positive | 30 Jul 2022 | |
Phase 2 | 30 | dtthijteen(gzrsdrshbr) = mybzylbfok uymnhmjuis (ilbdyzcqsd, 5.6) View more | Negative | 02 Jun 2022 | |||
Phase 1 | 31 | bkgcxnadez(pgccelcsye) = mucositis, fatigue, hyperglycemia and neutropenia reported as most common jvsmnoelpm (uefrgdljdx ) | - | 02 Jun 2022 |